an analysis of vasomotor , psychological , and physical symptoms of 136 women who were receiving piperazine oestrone sulphate ( ogen ) and conjugated equine oestrogens ( premarin ) after menopause has shown differences in responses which can be explained only if it is accepted that the two oestrogenic compounds have differing effects on various parts of the body .
C0014938
conjugated
C0014939
oestrogenic compounds